Cargando…

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study

BACKGROUND: Vedolizumab has become a standard treatment for the inflammatory bowel diseases ulcerative colitis (UC) and Crohn’s disease (CD). However, there is an ongoing debate on the ideal individual treatment algorithms and means to predict treatment response are not routinely established. AIMS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mühl, Laura, Becker, Emily, Müller, Tanja M., Atreya, Raja, Atreya, Imke, Neurath, Markus F., Zundler, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821503/ https://www.ncbi.nlm.nih.gov/pubmed/33482730 http://dx.doi.org/10.1186/s12876-021-01604-z

Ejemplares similares

Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
por: Becker, Emily, et al.
Publicado: (2022)

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis
por: Besendorf, Laura, et al.
Publicado: (2022)

α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
por: Melde, Michaela, et al.
Publicado: (2021)

Baseline levels of dynamic CD4(+) T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
por: Allner, Clarissa, et al.
Publicado: (2020)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality
por: Atreya, Raja, et al.
Publicado: (2022)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
por: Zundler, Sebastian, et al.
Publicado: (2023)

Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?
por: Atreya, Raja, et al.
Publicado: (2020)

Oligonucleotides—A Novel Promising Therapeutic Option for IBD
por: Scarozza, Patrizio, et al.
Publicado: (2019)

Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy
por: Wiendl, Maximilian, et al.
Publicado: (2021)

Anti‐β7 integrin treatment impedes the recruitment on non‐classical monocytes to the gut and delays macrophage‐mediated intestinal wound healing
por: Sommer, Katrin, et al.
Publicado: (2023)

Nr4a1-dependent non-classical monocytes are important for macrophage-mediated wound healing in the large intestine
por: Heidbreder, Karin, et al.
Publicado: (2023)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
por: Fischer, Anika, et al.
Publicado: (2016)

How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes
por: Atreya, Imke, et al.
Publicado: (2022)

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
por: Lichnog, Charlotte, et al.
Publicado: (2019)

Intestinal Mucosal Wound Healing and Barrier Integrity in IBD–Crosstalk and Trafficking of Cellular Players
por: Sommer, Katrin, et al.
Publicado: (2021)

Increased Motility and Suppression of Ex Vivo–Expanded Regulatory T Cells Designed for Adoptive Transfer Therapy in Ulcerative Colitis
por: Müller, Tanja M., et al.
Publicado: (2023)

Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis
por: Lindemann, Aylin, et al.
Publicado: (2023)

Deciphering Novel Mechanistic and Pharmacokinetic Effects of Tofacitinib in Intestinal Inflammation: Expect the Unexpected
por: Atreya, Raja, et al.
Publicado: (2021)

Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort
por: Bamias, Giorgos, et al.
Publicado: (2021)

Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease
por: Klenske, Entcho, et al.
Publicado: (2019)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Endoscopic Therapy in Inflammatory Bowel Diseases
por: Neumann, Helmut, et al.
Publicado: (2015)

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?
por: Abdullah, Abdullah, et al.
Publicado: (2020)

Role of the IL23/IL17 Pathway in Crohn’s Disease
por: Schmitt, Heike, et al.
Publicado: (2021)

Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2020)

Innate Lymphoid Cells as Regulators of Epithelial Integrity: Therapeutic Implications for Inflammatory Bowel Diseases
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2021)

Functional Contribution and Targeted Migration of Group-2 Innate Lymphoid Cells in Inflammatory Lung Diseases: Being at the Right Place at the Right Time
por: Wirtz, Stefan, et al.
Publicado: (2021)

ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure
por: Schulz-Kuhnt, Anja, et al.
Publicado: (2020)

Healing of the epithelial barrier in the ileum is superior to endoscopic and histologic remission for predicting major adverse outcomes in ulcerative colitis
por: Rath, Timo, et al.
Publicado: (2023)

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2021)

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

Deciphering the vedolizumab dosing conundrum in IBD: when less is more
por: Adolph, Timon Erik, et al.
Publicado: (2022)

The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis
por: Schmitt, Heike, et al.
Publicado: (2020)

Interplay of GTPases and Cytoskeleton in Cellular Barrier Defects during Gut Inflammation
por: López-Posadas, Rocío, et al.
Publicado: (2017)

Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD
por: Soendergaard, Christoffer, et al.
Publicado: (2018)

COVID-19 and immunomodulation in IBD
por: Neurath, Markus F
Publicado: (2020)

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f19iqiqflc9r0a9ct7kjebtda1